4-Aminopyridine, a Voltage-Gated K\(^+\) Channel Inhibitor, Attenuates Nitric Oxide-Mediated Vasodilation of Retinal Arterioles in Rats

Asami Mori,† Ryo Namekawa, Kenji Sakamoto,‡ Kunio Ishii, and Tsutomu Nakahara*

Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences; 5–9–1 Shirokane, Minato-ku, Tokyo 108–8641, Japan.

Received March 9, 2020; accepted April 20, 2020

Nitric oxide (NO) is an important regulator of the retinal blood flow. The present study aimed to determine the role of voltage-gated K\(^+\) (K\(_{\text{V}}\)) channels and ATP-sensitive K\(^+\) (K\(_{\text{ATP}}\)) channels in NO-mediated vasodilation of retinal arterioles in rats. In vivo, the retinal vasodilator responses were assessed by measuring changes in the diameter of retinal arterioles from ocular fundus images. Intravitreal injection of 4-aminopyridine (a K\(_{\text{V}}\) channel inhibitor), but not glibenclamide (a K\(_{\text{ATP}}\) channel blocker), significantly attenuated the retinal vasodilator response to the NO donor (±)-(E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexanamide (NOR3). Intravitreal injection of indomethacin (a non-selective cyclooxygenase inhibitor) also reduced the NOR3-induced retinal vasodilator response. The combination of 4-aminopyridine and indomethacin produced a greater reduction in the NOR3-induced response than either agent alone. 4-Aminopyridine had no significant effect on pinacidil (a K\(_{\text{ATP}}\) channel opener)-induced response. These results suggest that the vasodilatory effects of NO are mediated, at least in part, through the activation of 4-aminopyridine-sensitive K\(_{\text{V}}\) channels in the retinal arterioles of rats. NO exerts its dilatory effect on the retinal vasculature of rats through at least two mechanisms, activation of the K\(_{\text{V}}\) channels and enhancement of prostaglandin production.

Key words ATP-sensitive K\(^+\) channel; cyclooxygenase; nitric oxide; retinal blood vessel; voltage-gated K\(^+\) channel

INTRODUCTION

Nitric oxide (NO) is a potent vasodilator and plays an important role in regulating blood flow.\(^{11}\) In many cases, NO-mediated vasodilator responses are primarily mediated by guanosine 3',5'-cyclic monophosphate (cGMP), which is synthesized by NO-activated soluble guanylyl cyclases.\(^{11}\) However, in the retinal circulation, cGMP plays a minor role in NO-mediated vasodilator responses.\(^{2–5}\) In rats, the vasodilatory effects of NO on the retinal blood vessels are largely mediated by the cyclooxygenase-1/cAMP-mediated pathway.\(^{4,5}\) However, a notable residual NO-induced vasodilation observed in animals treated with indomethacin, a non-selective cyclooxygenase inhibitor, and SC-560, a selective cyclooxygenase-1 inhibitor, suggests the cAMP- and cGMP-independent vasodilatory mechanisms.

It has been reported that NO modulates multiple K\(^+\) channels, such as large-conductance Ca\(^{2+}\)-dependent K\(^+\) (BK\(_{\text{Ca}}\)) channels, voltage-gated K\(^+\) (K\(_{\text{V}}\)) channels, and ATP-sensitive K\(^+\) (K\(_{\text{ATP}}\)) channels, in the vascular smooth muscles.\(^{6–11}\) We previously demonstrated that the BK\(_{\text{Ca}}\) channel inhibitor, iberiotoxin, had no significant preventive effects on the retinal vasodilator responses to NO donors in rats.\(^{12}\) Therefore, in the present study, we investigated the roles of K\(_{\text{V}}\) channels and K\(_{\text{ATP}}\) channels in NO-mediated vasodilation of retinal arterioles of rats in vivo.

\(^{1}\) Present address: Laboratory of Medical Pharmacology, Department of Clinical & Pharmaceutical Sciences, Faculty of Pharma-Sciences, Teikyo University; 2–11–1 Kaga, Izbashi-ku, Tokyo 173–8605, Japan.

* To whom correspondence should be addressed. e-mail: nakaharat@pharm.kitasato-u.ac.jp

MATERIALS AND METHODS

All procedures in this study were approved by the Institutional Animal Care and Use Committee for Kitasato University (Approval No. T04-1, 17-28) and are in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research published by the US National Institutes of Health.

Experimental Procedures Thirty-five male Wistar rats (8–10 week-old) were maintained in a room with constant temperature (22 ± 2°C), humidity (55 ± 5%), and a 12-h light/dark cycle and were allowed free access to standard rat chow and tap water.

The experimental procedures used in this study were described in our previous reports.\(^{5,12,13}\) Briefly, rats were anesthetized with pentobarbital sodium (50 mg/kg, intraperitoneally; Nacalai Tesque, Kyoto, Japan). After the disappearance of the corneal reflex, tracheotomy was performed for artificial ventilation. Catheters were inserted into the femoral and jugular veins and the left femoral artery for the administration of drugs and measurement of arterial pressure, respectively. The heart rate was measured using a cardiotachometer triggered by the blood pressure pulse. The mean arterial pressure and heart rate were digitized at 1Hz (15BXW-H4, Dacs Giken, Okayama, Japan) and stored on the hard disk of a personal computer. Additional pentobarbital sodium (10 mg/kg) was administered as required.

The anesthetized rats were treated with tetrodotoxin (50 µg/kg, intravenously (i.v.); Nacalai Tesque) under artificial ventilation with room air (stroke volume, 10 mL/kg; frequency, 80 strokes/min) to prevent eye movements for capturing
fundus images at the same angle throughout the experiment. Treatment with tetrodotoxin reduced systemic blood pressure. Therefore, methoxamine hydrochloride (approx. 30μg/kg/min; Sigma-Aldrich, St. Louis, MO, U.S.A.) was infused into the jugular vein using a syringe pump (Model 1140-001, Harvard Apparatus, South Natick, MA, U.S.A.) to compensate for the drop in blood pressure.

The fundus photography and retinal arteriolar diameter measurement were performed as described in our previous studies.3,12,13 Briefly, hydroxyethylcellulose drops (Scopisol 15%; Senju Pharmaceutical, Osaka, Japan) were administered to the cornea to prevent drying of the eye; the optic disc was centered and focused in the field of view. Sodium fluorescein solution (10%, 0.8 mL/kg; Tokyo-Kasei Kogyo, Tokyo, Japan) solutions were injected into the femoral vein to enhance the blood vessel contrast in the retina. Fundus images were captured before and during intravenous infusion of the vasodilators using a digital camera (EOS7D, Canon, Tokyo, Japan) equipped with a bore scope-type objective lens for small animals (Model 01; Scalar, Tokyo, Japan). A region of the fundus image (5184×3456 pixels, pixel size = 1μm) containing a retinal arteriole was selected (138×276 pixels, 138×276μm), and the vessel diameter in the same region was measured throughout the experiment. The retinal vasodilator response was evaluated by measuring the changes in the diameter.

Protocols
Protocol 1: We examined the effects of 4-aminopyridine, indomethacin, and the combination of 4-aminopyridine and indomethacin on (±)-(E)-4-ethyl-2-[(E)-hydroxyiminol]-5-nitro-3-hexenamide (NOR3; Dojindo, Kumamoto, Japan)-induced vasodilation of retinal arterioles. 4-Aminopyridine (660 nmol; FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), indomethacin (10 nmol; Sigma-Aldrich), or 4-aminopyridine (660 nmol) plus indomethacin (10 nmol), in a total volume of 10μL, was injected into the vitreous cavity of the left eye before surgical procedures and tetrodotoxin treatment. The solutions for intravitreal injection were prepared with 0.12% Na2CO3 in saline. The control rats were similarly administered with the vehicle. Approximately 60 min after the intravitreal injection, intravenous infusion of NOR3 (0.5–10 μg/kg/min) was administered using a syringe pump (Model 1140-001, Harvard Apparatus). We also examined the effects of 4-aminopyridine on the KATP channel opener pinacidil (1–30 μg/kg/min; Sigma-Aldrich)-induced responses to determine whether 4-aminopyridine alters the vasodilator responses induced by the activation of other K+ channels.

Protocol 2: We examined the effects of the KATP channel blocker glibenclamide (20 mg/kg, i.v.; Nacalai Tesque) on NOR3 (0.5–10 μg/kg/min, i.v.)-induced vasodilation of the retinal arterioles. Glibenclamide was dissolved in 0.1 N NaOH and further diluted in 5% d-glucose solution (0.1 N NaOH: 5% d-glucose solution = 1:4). Glibenclamide, at the selected dose, markedly attenuated the retinal vasodilator responses induced by the doses of pinacidil.3

Statistical Analyses An unpaired t-test was used to compare the values between the groups and the data obtained from the multiple groups were analyzed by ANOVA followed by Tukey’s post-hoc test. A two-way ANOVA was used to compare the responses between the groups (PRISM6, GraphPad Software, San Diego, CA, U.S.A.). A p-value of <0.05 was considered statistically significant. All values are presented as the mean ± standard error of the mean (S.E.M.).

RESULTS
The baseline values of the retinal arteriolar diameter, mean arterial pressure, and heart rate could be adjusted to the same ranges (retinal arteriolar diameter, approx. 46μm; mean arterial pressure, approx. 115 mmHg; and heart rate, approx. 350 beats/min) in the experimental groups, by changing the methoxamine infusion rates.

Figure 1 shows the representative fundus images captured at baseline and 10 min after initiation of the intravenous infusion of NOR3 (10 μg/kg/min), which clearly dilated the retinal arterioles. The data are summarized in Fig. 2.

NOR3 (0.5–10 μg/kg/min, i.v.) increased the diameter of the retinal arterioles and reduced the MAP in a dose-dependent manner (Figs. 2A, B). However, it had no significant effect on the heart rate (Fig. 2C). Intravitreal injection of 4-aminopyridine (660 nmol/eye) significantly prevented NOR3-induced vasodilation of the retinal arterioles without affecting the depressor responses (Figs. 2A, B). Similarly, indomethacin (10 nmol/eye) prevented retinal vasodilation,
but not the depressor responses to NOR3. The combination of 4-aminopyridine and indomethacin reduced the retinal vasodilator response more than either drug alone.

Pinacidil (1–30 $\mu$g/kg/min, i.v.) also increased the diameter of the retinal arterioles and reduced the MAP in a dose-dependent manner (Figs. 3A, B). However, intravitreal injection of 4-aminopyridine did not affect pinacidil-induced vasodilation of the retinal arterioles (Fig. 3A). Thus, it is unlikely that 4-aminopyridine affects K\textsubscript{ATP} channels under our experimental conditions.

Glibenclamide (20 mg/kg, i.v.) had no significant effects on NOR3-induced responses (Fig. 4).

**DISCUSSION**

Our previous studies have shown that the NO-induced vasodilator response is mediated through the cyclooxygenase-1/prostaglandin I\textsubscript{2}/prostanoid IP receptor/cAMP signaling pathway in the retinal arterioles of rats. In the present study, we found that 4-aminopyridine, as well as indomethacin, significantly prevented the retinal vasodilator response to NOR3. The combination of 4-aminopyridine and indomethacin showed a further reduction of the NOR3-induced response. These results suggest that, in addition to the enhancement of prostaglandin production, activation of 4-aminopyridine-sensitive KV channels likely contributes to the NO-induced vasodilator response in the retinal arterioles of rats.

Multiple K\textsuperscript{+} channels contribute to the regulation of blood flow in various vascular beds. NO is one of the modulators of the activities of these multiple K\textsuperscript{+} channels in vascular smooth muscles. Our present results suggest that NO activates 4-aminopyridine-sensitive KV channels, thereby dilating retinal arterioles of rats. However, it is unlikely that NO affects...
the activity of BK<sub>Ca</sub> and K<sub>ATP</sub> channels in the retinal arterioles because neither the BK<sub>Ca</sub> channel inhibitor iberiotoxin nor the K<sub>ATP</sub> channel blocker glibenclamide (current study) attenuated NOR3-induced vasodilatation of the retinal arterioles.

NO could activate the K<sup>+</sup> channels directly or through a cGMP-dependent mechanism. Our previous studies demonstrated that a soluble guanylyl cyclase inhibitor failed to prevent retinal vasodilator responses to NO donors. Therefore, the involvement of cGMP-dependent mechanism in the activation of 4-aminopyridine-sensitive K<sub>V</sub> channels may be unlikely in the retinal arterioles of rats. Vasodilators that act through the Gi/Go-coupled receptors and the cAMP signaling pathway also activate the 4-aminopyridine-sensitive K<sub>V</sub> channels. To test the possibility that NO activates 4-aminopyridine-sensitive K<sub>V</sub> channels through the cGMP-dependent mechanism, we examined the effects of 4-aminopyridine on NOR3-induced retinal vasodilatation following blockade of the cyclooxygenase-1/prostaglandin I<sub>2</sub>/prostanoid IP receptor/cAMP signaling pathway by indomethacin. The results suggest that NO activates the 4-aminopyridine-sensitive K<sub>V</sub> channels independently of cAMP in the retinal arterioles of rats. Thus, NO may activate 4-aminopyridine-sensitive K<sub>V</sub> channels in cAMP- or cGMP-independent mechanisms in the retinal vascular bed. With regard to the direct action, NO modifies the K<sup>+</sup> channel or a closely associated regulatory protein, by S-nitrosylation. In human cardiac fibroblasts, the effects of NO on K<sub>V</sub> channels are not mediated by S-nitrosylation. However, 4-aminopyridine inhibits K<sub>V</sub>1–4 channel subtypes, and it remains unclear which subtypes are involved NO-induced vasodilatation of retinal arterioles. Therefore, NO may directly affect activity of 4-aminopyridine-sensitive K<sub>V</sub> channels expressed in rat retinal arterioles.

The mechanism by which NO preferentially stimulates the cGMP-independent pathway remains to be elucidated. Previous immunohistochemical studies revealed that vascular smooth muscle cells of the retinal blood vessels showed a low expression of soluble guanylyl cyclase. Because of the low expression level of soluble guanylyl cyclase in the retinal blood vessels, NO may preferentially interact with cyclooxygenase<sup>22–25</sup> and 4-aminopyridine-sensitive K<sub>V</sub> channels, but not with soluble guanylyl cyclase.

Our present results suggest that 4-aminopyridine-sensitive K<sub>V</sub> channels (K<sub>V</sub>1–4) contribute, at least in part, to the vasodilatory effects of NO on rat retinal arterioles. However, vascular smooth muscle cells have been reported to express members of the K<sub>V</sub>1–4, K<sub>V</sub>6, K<sub>V</sub>7, K<sub>V</sub>9, and K<sub>V</sub>11 families of K<sub>V</sub> channels. Other families of K<sub>V</sub> channels (e.g., K<sub>V</sub>7) might contribute to the regulation of retinal vascular tone. Therefore, further studies are needed to elucidate the expression of K<sub>V</sub> channel subtypes in rat retinal arterioles and to examine the involvement of other families of K<sub>V</sub> channels in NO-induced vasodilatation of retinal arterioles.

In summary, we found that 4-aminopyridine-sensitive K<sub>V</sub> channels contribute, at least in part, to the vasodilatory effects of NO on the retinal arterioles of rats. In the rat retinal circulation, the vasodilator action of NO is mediated through at least two mechanisms, opening of 4-aminopyridine-sensitive K<sub>V</sub> channels and enhancement of prostaglandin production.

Acknowledgments This study was supported by the Kita-sato University Research Grant for Young Researchers (A.M.) and JSPS KAKENHI (Grant Numbers: 22790260 A.M., and 24790261 A.M.).

Conflict of Interest The authors declare no conflict of interest.

REFERENCES

1. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev., 43, 109–142 (1991).
2. Hardy P, Abran D, Hou X, Lahalle I, Peri KG, Asselin P, Varma DR, Chemtob S. A major role for prostacyclin in nitric oxide-induced ocular vasorelaxation in the piglet. Circ. Res., 83, 721–729 (1998).
3. Ogawa N, Saito M, Mori A, Sakamoto K, Kametaka S, Nakahara T, Ishii K. Vasodilator effect of nicorandil on retinal blood vessels in rats. Naunyn Schmiedebergs Arch. Pharmacol., 375, 323–328 (2007).
4. Ogawa N, Mori A, Hasebe M, Hoshino M, Saito M, Sakamoto K, Nakahara T, Ishii K. Nitric oxide dilates rat retinal blood vessels by cyclooxygenase-dependent mechanisms. Am. J. Physiol. Regul. Integr. Comp. Physiol., 297, R968–R977 (2009).
5. Mori A, Namekawa R, Hasebe M, Saito M, Sakamoto K, Nakahara T, Ishii K. Involvement of prostaglandin I<sub>2</sub> in nitric oxide-induced vasodilatation of retinal arterioles in rats. Eur. J. Pharmacol., 764, 249–255 (2015).
6. Archer SL, Huang JM, Hampl V, Nelson DP, Shultz PJ, Weir EK. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K<sub>V</sub> channel by cGMP-dependent protein kinase. Proc. Natl. Acad. Sci. U.S.A., 91, 7583–7587 (1994).
7. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature, 368, 850–853 (1994).
8. Murphy ME, Brayden JE. Nitric oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive potassium channels. J. Physiol., 486, 47–58 (1995).
9. Yuan XJ, Tod ML, Rubin LJ, Blaustein MP. NO hyperpolarizes pulmonary artery smooth muscle cells and decreases the intracellular Ca<sup>2+</sup> concentration by activating voltage-gated K<sub>V</sub> channels. Proc. Natl. Acad. Sci. U.S.A., 93, 10489–10494 (1996).
10. Zhao YJ, Wang J, Rubin LJ, Yuan XJ. Inhibition of K<sub>V</sub> and K<sub>Ca</sub> channels antagonizes NO-induced relaxation in pulmonary artery. Am. J. Physiol., 272, H1904–H1912 (1997).
11. Mistry DK, Garland CJ. Nitric oxide (NO)-induced activation of large conductance Ca<sup>2+</sup>–dependent K<sub>V</sub> channels (BK<sub>Ca</sub>) in smooth muscle cells isolated from the rat mesenteric artery. Br. J. Pharmacol., 124, 1311–1340 (1998).
12. Mori A, Suzuki S, Sakamoto K, Nakahara T, Ishii K. Role of calcium-activated potassium channels in acetylcholine-induced vasodilatation of rat retinal arterioles in vivo. Naunyn Schmiedebergs Arch. Pharmacol., 383, 27–34 (2011).
13. Mori A, Saito M, Sakamoto K, Narita M, Nakahara T, Ishii K. Stimulation of prostanoid IP and EP<sub>2</sub> receptors dilates retinal arterioles and increases retinal and choroidal blood flow in rats. Eur. J. Pharmacol., 570, 135–141 (2007).
14. Faraci FM, Sobe CG. Role of potassium channels in regulation of cerebral vascular tone. J. Cereb. Blood Flow Metab., 18, 1047–1063 (1998).
15. Standen NB, Quayle JM. K<sub>V</sub> channel modulation in arterial smooth muscle. Acta Physiol. Scand., 164, 549–557 (1998).
16. Irvine JC, Favalaro JI, Kemp-Harper BK. NO activates soluble guanylate cyclase and K<sub>V</sub> channels to vasodilate resistance arteries. Hypertension, 41, 1301–1307 (2003).
17. Jackson WF. K<sub>V</sub> channels and the regulation of vascular smooth muscle tone. Microcirculation, 25, e12421 (2018).
18. Sokolovskil V, Blätt MR. Nitric oxide block of outward-rectifying potassium channels.
K⁺ channels indicates direct control by protein nitrosylation in guard cells. Plant Physiol., 136, 4275–4284 (2004).  
19) Gómez R, Caballero R, Barana A, Amorós I, Calvo E, López JA, Klein H, Vaquero M, Osuna L, Atienza F, Almendral J, Pinto A, Tamargo J, Delpón E. Nitric oxide increases cardiac IK1 by nitrosylation of cysteine 76 of Kir2.1 channels. Circ. Res., 105, 383–392 (2009).  
20) Bae H, Choi J, Kim YW, Lee D, Kim JH, Ko JH, Bang H, Kim T, Lim I. Effects of nitric oxide on voltage-gated K⁺ currents in human cardiac fibroblasts through the protein kinase G and protein kinase A pathways but not through S-nitrosylation. Int. J. Mol. Sci., 19, E814 (2018).  
21) Ding JD, Weinberg RJ. Distribution of soluble guanylyl cyclase in rat retina. J. Comp. Neurol., 500, 734–745 (2007).  
22) Mollace V, Mascoli C, Masini E, Cuzzocrea S, Salvemini D. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol. Rev., 57, 217–252 (2005).  
23) Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc. Natl. Acad. Sci. U.S.A., 90, 7240–7244 (1993).  
24) Salvemini D, Currie MG, Mollace V. Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators. J. Clin. Invest., 97, 2562–2568 (1996).  
25) Salvemini D. Regulation of cyclooxygenase enzymes by nitric oxide. Cell. Mol. Life Sci., 53, 576–582 (1997).